PharmGen Science Inc (004720) - Total Assets
Based on the latest financial reports, PharmGen Science Inc (004720) holds total assets worth ₩331.46 Billion KRW (≈ $224.63 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 004720 net assets for net asset value and shareholders' equity analysis.
PharmGen Science Inc - Total Assets Trend (2004–2024)
This chart illustrates how PharmGen Science Inc's total assets have evolved over time, based on quarterly financial data.
PharmGen Science Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
PharmGen Science Inc's total assets of ₩331.46 Billion consist of 30.5% current assets and 69.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 10.4% |
| Accounts Receivable | ₩39.30 Billion | 10.8% |
| Inventory | ₩31.84 Billion | 8.8% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩7.13 Billion | 2.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how PharmGen Science Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of PharmGen Science Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PharmGen Science Inc's current assets represent 30.5% of total assets in 2024, an increase from 0.0% in 2004.
- Cash Position: Cash and equivalents constituted 10.4% of total assets in 2024, up from 2.7% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 68.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 10.8% of total assets.
PharmGen Science Inc Competitors by Total Assets
Key competitors of PharmGen Science Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Roche Holding AG
SW:ROG
|
Switzerland | CHF100.70 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
CSPC Pharmaceutical Group Limited
F:CVG
|
Germany | €46.00 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX114.07 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥13.11 Billion |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.83 Billion |
PharmGen Science Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.25 | 1.62 | 1.99 |
| Quick Ratio | 1.44 | 1.17 | 1.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩52.14 Billion | ₩39.57 Billion | ₩37.21 Billion |
PharmGen Science Inc - Advanced Valuation Insights
This section examines the relationship between PharmGen Science Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.36 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 8.2% |
| Total Assets | ₩363.45 Billion |
| Market Capitalization | $62.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values PharmGen Science Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: PharmGen Science Inc's assets grew by 8.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for PharmGen Science Inc (2004–2024)
The table below shows the annual total assets of PharmGen Science Inc from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩363.45 Billion ≈ $246.31 Million |
+8.20% |
| 2023-12-31 | ₩335.92 Billion ≈ $227.65 Million |
+5.84% |
| 2022-12-31 | ₩317.39 Billion ≈ $215.09 Million |
+44.06% |
| 2021-12-31 | ₩220.32 Billion ≈ $149.31 Million |
+62.55% |
| 2020-12-31 | ₩135.54 Billion ≈ $91.86 Million |
+35.50% |
| 2019-12-31 | ₩100.03 Billion ≈ $67.79 Million |
+1.88% |
| 2018-12-31 | ₩98.19 Billion ≈ $66.54 Million |
+43.39% |
| 2017-12-31 | ₩68.48 Billion ≈ $46.41 Million |
+6.50% |
| 2016-12-31 | ₩64.30 Billion ≈ $43.58 Million |
+38.43% |
| 2015-12-31 | ₩46.45 Billion ≈ $31.48 Million |
+10.48% |
| 2014-12-31 | ₩42.04 Billion ≈ $28.49 Million |
+6.90% |
| 2013-12-31 | ₩39.33 Billion ≈ $26.65 Million |
-7.71% |
| 2012-12-31 | ₩42.61 Billion ≈ $28.88 Million |
-0.49% |
| 2011-12-31 | ₩42.82 Billion ≈ $29.02 Million |
-35.57% |
| 2005-12-31 | ₩66.47 Billion ≈ $45.04 Million |
+34.32% |
| 2004-12-31 | ₩49.49 Billion ≈ $33.54 Million |
-0.83% |
| 2004-09-30 | ₩49.90 Billion ≈ $33.82 Million |
-- |
About PharmGen Science Inc
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed i… Read more